Denali Therapeutics Inc. (NASDAQ:DNLI) Receives Average Recommendation of "Buy" from Analysts

Denali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report) has earned an average recommendation of "Buy" from the seventeen analysts that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating, fourteen have issued a buy rating and two have given a strong buy rating to the company. The average 1 year price target among analysts that have covered the stock in the last year is $33.79.

A number of equities analysts have commented on the stock. Wedbush decreased their price objective on shares of Denali Therapeutics from $32.00 to $30.00 and set an "outperform" rating on the stock in a report on Wednesday, May 7th. HC Wainwright lowered their target price on Denali Therapeutics from $80.00 to $32.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th. Oppenheimer decreased their price objective on Denali Therapeutics from $50.00 to $42.00 and set an "outperform" rating on the stock in a report on Monday, March 3rd. The Goldman Sachs Group decreased their price target on shares of Denali Therapeutics from $45.00 to $40.00 and set a "buy" rating on the stock in a research note on Tuesday, January 28th. Finally, Cantor Fitzgerald upgraded shares of Denali Therapeutics from a "neutral" rating to an "overweight" rating in a research report on Thursday, April 10th.

Hedge Funds Weigh In On Denali Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Caitong International Asset Management Co. Ltd increased its holdings in Denali Therapeutics by 277.0% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 2,111 shares of the company's stock worth $29,000 after purchasing an additional 1,551 shares in the last quarter. Sterling Capital Management LLC grew its stake in shares of Denali Therapeutics by 589.9% in the fourth quarter. Sterling Capital Management LLC now owns 1,773 shares of the company's stock worth $36,000 after purchasing an additional 1,516 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S bought a new position in Denali Therapeutics during the 1st quarter worth $41,000. GF Fund Management CO. LTD. bought a new stake in shares of Denali Therapeutics in the 4th quarter valued at about $62,000. Finally, Point72 Hong Kong Ltd acquired a new stake in shares of Denali Therapeutics in the fourth quarter valued at about $65,000. 92.92% of the stock is currently owned by institutional investors and hedge funds.

Denali Therapeutics Trading Down 2.1%

NASDAQ DNLI opened at $13.96 on Thursday. The stock has a 50 day moving average of $14.15 and a 200-day moving average of $19.83. Denali Therapeutics has a 12 month low of $10.57 and a 12 month high of $33.33. The company has a market cap of $2.03 billion, a PE ratio of -5.06 and a beta of 1.49.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported ($0.78) EPS for the quarter, missing analysts' consensus estimates of ($0.71) by ($0.07). During the same period last year, the company posted ($0.68) earnings per share. As a group, sell-side analysts predict that Denali Therapeutics will post -2.71 EPS for the current fiscal year.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.